These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16312606)

  • 1. Teicoplanin in the therapy of gram-positive infections: an open non-randomized study.
    De Lalla F; Rinaldi E; Santoro D; Rizzardini G; Martello P; Guaglianone MH
    J Chemother; 1989 Jul; 1(4 Suppl):719-21. PubMed ID: 16312606
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vancomycin and teicoplanin: differential aspects].
    Cobo J
    Enferm Infecc Microbiol Clin; 1995 Dec; 13(10):600-10. PubMed ID: 8808477
    [No Abstract]   [Full Text] [Related]  

  • 3. [The use of teicoplanin for Gram-positive infections in patients with kidney transplantation].
    Jákics J; Gálffy Z; Hernold L; Rácz A; Perner F
    Orv Hetil; 1996 Jun; 137(25):1355-8. PubMed ID: 8757082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of teicoplanin's therapeutic efficacy in immunocompromised patients with staphylococcal sepsis.
    Orani A; Fossati M; Castelli N; Sala A
    J Chemother; 1989 Jul; 1(4 Suppl):716-9. PubMed ID: 16312605
    [No Abstract]   [Full Text] [Related]  

  • 5. [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
    Debbag R; Paganini H; Gómez S; Casimir L; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():48-51. PubMed ID: 12481489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
    Wang JT; Liao HI; Wu Lin FL; Chang SC
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis.
    Brink AJ; Richards GA; Cummins RR; Lambson J;
    Int J Antimicrob Agents; 2008 Nov; 32(5):455-8. PubMed ID: 18718742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefixime once-a-day in the treatment of lower respiratory tract infections in adults.
    Capelli O; Bonucchi ME; Ragno T; Azzolini L; Prandi E; Lega M; Toraldo MD; Velluti G
    J Chemother; 1989 Jul; 1(4 Suppl):775-8. PubMed ID: 16312634
    [No Abstract]   [Full Text] [Related]  

  • 9. Ambulatory treatment with intramuscular ceftriaxone.
    Schlaeffer F
    J Chemother; 1989 Jul; 1(4 Suppl):655-6. PubMed ID: 16312577
    [No Abstract]   [Full Text] [Related]  

  • 10. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of teicoplanin in gram-positive pulmonary infections.
    Sanduzzi A; Nani E; Sarno M; Vatrella A; Parrella R; Mattiello A
    J Chemother; 1991 Jan; 3 Suppl 1():224-6. PubMed ID: 12041771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections.
    Del Pozo JL; Alonso M; Serrera A; Hernaez S; Aguinaga A; Leiva J
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):208-12. PubMed ID: 19026506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial drug discovery and development--SRI's 11th Annual Summit. Antibacterial trends and current research.
    Silver LL
    IDrugs; 2006 Jun; 9(6):394-7. PubMed ID: 16752305
    [No Abstract]   [Full Text] [Related]  

  • 16. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ; Goff DA
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy of intraventricularly administered vancomycin in the case of central nervous system infection caused by enterococcus faecalis].
    Czaban SL; Lebkowski WJ; Krajewski JP; Borkowski J
    Wiad Lek; 2002; 55(9-10):617-25. PubMed ID: 12607418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical effectiveness of teicoplanin in the treatment of Gram-positive bacterial infections in children].
    Careddu P; Boccazzi A
    G Ital Chemioter; 1991; 38(1-3):175-6. PubMed ID: 1365583
    [No Abstract]   [Full Text] [Related]  

  • 19. [First case of infection due to vancomycin resistant Enterococcus faecalis in New Caledonia].
    Garin B; Barny S; Lechevallier S; Agathe-Nerine J
    Med Mal Infect; 2006 May; 36(5):297-8. PubMed ID: 16631333
    [No Abstract]   [Full Text] [Related]  

  • 20. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.